Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Equity Ratio (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Equity Ratio readings, the most recent being 0.38 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 19.79% to 0.38 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.38, a 19.79% increase, with the full-year FY2025 number at 0.23, down 32.59% from a year prior.
  • Equity Ratio hit 0.38 in Q4 2025 for Enanta Pharmaceuticals, up from 0.23 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.93 in Q1 2021 to a low of 0.23 in Q3 2025.
  • Median Equity Ratio over the past 5 years was 0.47 (2023), compared with a mean of 0.6.
  • Biggest five-year swings in Equity Ratio: plummeted 51.32% in 2024 and later rose 19.79% in 2025.
  • Enanta Pharmaceuticals' Equity Ratio stood at 0.87 in 2021, then fell by 0.78% to 0.87 in 2022, then plummeted by 48.27% to 0.45 in 2023, then fell by 28.38% to 0.32 in 2024, then grew by 19.79% to 0.38 in 2025.
  • The last three reported values for Equity Ratio were 0.38 (Q4 2025), 0.23 (Q3 2025), and 0.26 (Q2 2025) per Business Quant data.